Curexo unveils artificial joint surgery robot TMAX at AAOS 2023

Curexo, a South Korean medical robot company, said on Tuesday that it had unveiled its artificial joint surgery robot "TMAX" at AAOS 2023, the world’s largest orthopedic surgery conference, which took place for five days from March 11 in Las Vegas.

TMAX is a product that combines Curexo’s artificial joint surgery robot "QUBIS-Joint" with TSI’s artificial joint surgery planning software "TPLAN." TSI is a US subsidiary of Curexo.

The two companies have been preparing for TMAX’s entry into the US market for the past year. Curexo is responsible for system development and production, while TSI handles FDA approval as well as marketing and sales.

They aim to apply for FDA approval of TMAX by the first half of this year and receive approval by the end of the year. Curexo plans to sell TMAX in Europe as well as in the US.

At AAOS 2023, TSI also exhibited its own portable orthopedic surgery device "TMINI." TMINI is currently undergoing a US approval review. It is expected to enter the US market by the first half of this year.

Write to Jae-Young Han at jyhan@hankyung.com